Fecal microbiota transplantation (FMT) is an emerging therapy for recurrent or refractory Clostridioides difficile infection and is being actively investigated for other conditions. We describe two patients in whom extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli bacteremia occurred after they had undergone FMT in two independent clinical trials; both cases were linked to the same stool donor by means of genomic sequencing. One of the patients died. Enhanced donor screening to limit the transmission of microorganisms that could lead to adverse infectious events and continued vigilance to define the benefits and risks of FMT across different patient populations are warranted.

中文翻译：

---

粪便微生物菌群移植所传播的抗药性大肠杆菌细菌血症。

粪便微生物菌群移植（FMT）是一种针对复发性或难治性梭状芽胞杆菌艰难梭菌感染的新兴疗法，目前正在积极研究其他病症。我们在两个独立的临床试验中描述了两名患者，他们在接受FMT治疗后发生了产生广谱β-内酰胺酶（ESBL）的大肠杆菌菌血症。两种病例均通过基因组测序与同一个粪便供体相连。其中一名患者死亡。必须加强捐献者筛选，以限制可能导致不良感染事件的微生物传播，并继续保持警惕，以定义不同患者人群中FMT的益处和风险。